SCHEMBL17593238

SCHEMBL17593238

COCCn1nc(-c2ccccc2)cc1C(=O)Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ THRB P10828 1/20 0.56
▸ KDM4E B2RXH2 7/20 0.54
▸ KMT2A Q03164 6/20 0.54
▸ MEN1 O00255 4/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ ALDH1A1 P00352 3/20 0.53
▸ CNR1 P21554 1/20 0.53
▸ RXFP1 Q9HBX9 3/20 0.53
▸ POLB P06746 3/20 0.52
▸ MAPK1 P28482 2/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ HPGD P15428 1/20 0.52
▸ NPSR1 Q6W5P4 1/20 0.52
▸ PKM P14618 1/20 0.51
▸ GAA P10253 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17593272 0.90 KDM4E (0.54) THRBKDM4EKMT2AMEN1TDP1
SCHEMBL17593269 0.89 MAPK1 (0.60) THRBKDM4EKMT2AMEN1TDP1
SCHEMBL17593206 0.88 KDM4E (0.53) THRBKDM4EKMT2AMEN1TDP1
SCHEMBL17593243 0.87 KDM4E (0.62) THRBKDM4EKMT2AMEN1TDP1
SCHEMBL17593082 0.82 KDM4E (0.54) THRBKDM4EKMT2AMEN1TDP1
SCHEMBL17593069 0.80 TDP1 (0.58) THRBKDM4EKMT2AMEN1TDP1
SCHEMBL17593251 0.80 L3MBTL1 (0.40) KDM4EKMT2AMEN1ALDH1A1CNR1
SCHEMBL2565517 0.76 ALDH1A1 (0.56) KDM4EKMT2AMEN1ALDH1A1POLB
SCHEMBL17593156 0.76 KMT2A (0.57) THRBKDM4EKMT2AMEN1TDP1
SCHEMBL17592902 0.75 KDM4E (0.68) THRBKDM4EKMT2AMEN1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016040449-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2016-03-17 — — WO disclosed
Send feedback